Do analysts rate ORGS or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or PRPH more profitable?

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% ProPhase Labs -825.01% -482.05% -88.90%

Do analysts recommend SHPH or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SHPH or PRPH?

In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than ProPhase Labs. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 1 mentions for ProPhase Labs. Shuttle Pharmaceuticals' average media sentiment score of 0.76 beat ProPhase Labs' score of 0.08 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shuttle Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PRPH or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PRPH or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRPH or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets ProPhase Labs -825.01% -482.05% -88.90% Vaccinex N/A N/A -383.58%

Does the media prefer PRPH or VCNX?

In the previous week, ProPhase Labs and ProPhase Labs both had 1 articles in the media. ProPhase Labs' average media sentiment score of 0.08 beat Vaccinex's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProPhase Labs (PRPH) Competitors

$0.09 -0.01 (-5.90%)

As of 06/29/2026 03:18 PM Eastern

Compare

PRPH vs. ORGS, CASI, SHPH, QLGN, and VCNX

Should you buy ProPhase Labs stock or one of its competitors? MarketBeat compares ProPhase Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProPhase Labs include Orgenesis (ORGS), CASI Pharmaceuticals (CASI), Shuttle Pharmaceuticals (SHPH), Qualigen Therapeutics (QLGN), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.

How does ProPhase Labs compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
ProPhase Labs	-825.01%	-482.05%	-88.90%

ProPhase Labs has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
ProPhase Labs	$5.06M	0.11	-$53.36M	-$3.90	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ProPhase Labs had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Orgenesis. ProPhase Labs' average media sentiment score of 0.08 beat Orgenesis' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Orgenesis	Neutral
ProPhase Labs	Neutral

Orgenesis has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ProPhase Labs beats Orgenesis on 10 of the 14 factors compared between the two stocks.

How does ProPhase Labs compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

CASI Pharmaceuticals has higher revenue and earnings than ProPhase Labs. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
ProPhase Labs	$5.06M	0.11	-$53.36M	-$3.90	N/A

CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CASI Pharmaceuticals has a net margin of -183.93% compared to ProPhase Labs' net margin of -825.01%. CASI Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
ProPhase Labs	-825.01%	-482.05%	-88.90%

In the previous week, ProPhase Labs had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for CASI Pharmaceuticals. ProPhase Labs' average media sentiment score of 0.08 beat CASI Pharmaceuticals' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
ProPhase Labs	Neutral

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CASI Pharmaceuticals beats ProPhase Labs on 11 of the 16 factors compared between the two stocks.

How does ProPhase Labs compare to Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Shuttle Pharmaceuticals has higher earnings, but lower revenue than ProPhase Labs. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
ProPhase Labs	$5.06M	0.11	-$53.36M	-$3.90	N/A

Shuttle Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Shuttle Pharmaceuticals' return on equity of -408.34% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
ProPhase Labs	-825.01%	-482.05%	-88.90%

In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than ProPhase Labs. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 1 mentions for ProPhase Labs. Shuttle Pharmaceuticals' average media sentiment score of 0.76 beat ProPhase Labs' score of 0.08 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shuttle Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Shuttle Pharmaceuticals beats ProPhase Labs on 7 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Qualigen Therapeutics?

ProPhase Labs (NASDAQ:PRPH) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Qualigen Therapeutics has lower revenue, but higher earnings than ProPhase Labs. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.11	-$53.36M	-$3.90	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Qualigen Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Qualigen Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Qualigen Therapeutics	N/A	N/A	-202.16%

ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, ProPhase Labs had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Qualigen Therapeutics. ProPhase Labs' average media sentiment score of 0.08 beat Qualigen Therapeutics' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media.

Company	Overall Sentiment
ProPhase Labs	Neutral
Qualigen Therapeutics	Neutral

Summary

ProPhase Labs beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Vaccinex?

ProPhase Labs (NASDAQ:PRPH) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ProPhase Labs has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Vaccinex	N/A	N/A	-383.58%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, ProPhase Labs and ProPhase Labs both had 1 articles in the media. ProPhase Labs' average media sentiment score of 0.08 beat Vaccinex's score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaccinex has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.11	-$53.36M	-$3.90	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

Summary

Vaccinex beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$567K	$3.02B	$6.83B	$12.19B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.02	19.67	25.79	24.59
Price / Sales	0.11	353.35	544.64	103.13
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.04	4.25	10.88	6.49
Net Income	-$53.36M	$64.45M	$3.57B	$336.61M
7 Day Performance	N/A	3.73%	2.50%	1.20%
1 Month Performance	N/A	4.01%	0.87%	0.20%
1 Year Performance	N/A	34.35%	36.39%	30.15%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	0.1681 of 5 stars	$0.09 -5.9%	N/A	-97.4%	$567K	$5.06M	N/A	130	Upcoming Earnings Gap Down
ORGS Orgenesis	N/A	$0.50 -4.8%	N/A	N/A	$2.56M	$662K	N/A	150	Gap Down
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
SHPH Shuttle Pharmaceuticals	0.7786 of 5 stars	$3.84 +9.1%	N/A	-90.5%	$2.46M	N/A	N/A	5
QLGN Qualigen Therapeutics	N/A	$1.36 -6.8%	N/A	-69.7%	$2.31M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. ORGS, CASI, SHPH, QLGN, and VCNX

How does ProPhase Labs compare to Orgenesis?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Summary

How does ProPhase Labs compare to Shuttle Pharmaceuticals?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Summary

How does ProPhase Labs compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. ORGS, CASI, SHPH, QLGN, and VCNX

How does ProPhase Labs compare to Orgenesis?

Is ORGS or PRPH more profitable?

Which has stronger valuation & earnings, ORGS or PRPH?

Do analysts rate ORGS or PRPH?

Does the media favor ORGS or PRPH?

Which has more risk and volatility, ORGS or PRPH?

Do institutionals & insiders believe in ORGS or PRPH?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Which has preferable earnings and valuation, CASI or PRPH?

Which has more volatility & risk, CASI or PRPH?

Do analysts recommend CASI or PRPH?

Is CASI or PRPH more profitable?

Does the media favor CASI or PRPH?

Do institutionals & insiders hold more shares of CASI or PRPH?

Summary

How does ProPhase Labs compare to Shuttle Pharmaceuticals?

Which has stronger valuation and earnings, SHPH or PRPH?

Is SHPH or PRPH more profitable?

Does the media favor SHPH or PRPH?

Which has more volatility and risk, SHPH or PRPH?

Do institutionals and insiders hold more shares of SHPH or PRPH?

Do analysts recommend SHPH or PRPH?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Which has stronger earnings & valuation, PRPH or QLGN?

Do analysts rate PRPH or QLGN?

Do insiders & institutionals believe in PRPH or QLGN?

Is PRPH or QLGN more profitable?

Which has more volatility and risk, PRPH or QLGN?

Does the media refer more to PRPH or QLGN?

Summary

How does ProPhase Labs compare to Vaccinex?

Do insiders & institutionals hold more shares of PRPH or VCNX?

Which has more risk & volatility, PRPH or VCNX?

Is PRPH or VCNX more profitable?

Do analysts prefer PRPH or VCNX?

Does the media prefer PRPH or VCNX?

Which has stronger valuation and earnings, PRPH or VCNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools